Assessment of thyroid-specific quality of life in patients with benign symptomatic thyroid nodules treated with radiofrequency or ethanol ablation: a prospective multicenter study
Ultrasonography 2022³â 41±Ç 1È£ p.204 ~ p.211
Á¤¼Ò¿µ(Jeong So-Yeong) - University of Ulsan College of Medicine Asan Medical Center Department of Radiology
ÇÏÀºÁÖ(Ha Eun-Ju) - Ajou University School of Medicine Department of Radiology
¹éÁ¤È¯(Baek Jung-Hwan) - University of Ulsan College of Medicine Asan Medical Center Department of Radiology
±èÅ¿µ(Kim Tae-Yong) - University of Ulsan College of Medicine Asan Medical Center Department of Internal Medicine
ÀÌÀ¯¹Ì(Lee Yu-Mi) - University of Ulsan College of Medicine Asan Medical Center Department of Surgery
ÀÌÁ¤Çö(Lee Jeong-Hyun) - University of Ulsan College of Medicine Asan Medical Center Department of Radiology
ÀÌÁ¤ÈÆ(Lee Jeong-Hun) - Ajou University School of Medicine Department of Surgery
Abstract
Purpose: Radiofrequency ablation (RFA) and ethanol ablation (EA) are effective and safe for benign symptomatic thyroid nodules (BSTNs). However, relatively little is known about the effects of these procedures on patients¡¯ quality of life (QoL). This prospective, multicenter study evaluated the effects of RFA and EA on changes in thyroid-specific QoL in patients with BSTNs and assessed the volume reduction and safety of these procedures.
Methods: Eighty-six consecutive patients with 86 BSTNs were prospectively included from two medical centers. RFA was performed for 55 BSTNs with solidity ¡Ã50% and EA was performed for 31 BSTNs with solidity <50%. QoL was evaluated using an 11-scale, multiple-choice thyroid-specific QoL questionnaire. Nodule characteristics and QoL were evaluated at diagnosis and 1, 6, and 12 months after treatment. Overall QoL was rated from 0 (good) to 4 (poor).
Results: The mean longest size and volume of the index nodule were 4.2¡¾1.5 cm and 21.6¡¾22.1 mL, respectively. Patients received 1.1 treatments on average (range, 1 to 2). Significant post-treatment volume reductions were noted; however, the EA group showed a higher volume reduction than the RFA group at 1 (78.7%-16.1% vs. 49.1%-15.8%), 6 (86.3%-21.7% vs. 73.0%-14.5%), and 12 (90.9%-14.9% vs. 80.3%-12.4%) months. The score for each scale of the QoL questionnaire improved significantly during follow-up (all P<0.001). Overall QoL improved significantly, from 1.7¡¾0.9 at diagnosis to 0.6¡¾0.7 at the 12-month follow-up (P<0.001). There were no major complications.
Conclusion: Both RFA and EA are safe and effective in reducing nodule volume and improving thyroid-specific QoL in patients with BSTNs.
Å°¿öµå
Radiofrequency ablation, Ethanol, Quality of life, Thyroid nodule
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
Significant post-treatment volume reductions were noted; however, the EA group showed a higher volume reduction than the RFA group at 1 , 6 , and 12 months.